2025-04-11 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**0. Overview:** Eli Lilly and Co. is a global pharmaceutical company that researches, develops, manufactures, and markets pharmaceutical products.

**1. Performance Comparison with S&P 500 (VOO):**

LLY's cumulative return is significantly higher than that of the S&P 500 (VOO).

* **LLY Cumulative Return:** 269.19%
* **VOO Cumulative Return:** 65.78%
* **Return Difference:** 203.4%  (This represents the difference in cumulative returns at the end of the period. It is not an annualized return.)
* **Relative Divergence:** 67.9% (This means LLY's performance relative to VOO is in the 67.9th percentile of its historical range of outperformance/underperformance.)

The provided alpha and beta values indicate that LLY has consistently outperformed the market (positive alpha) with higher volatility than the market (beta > 1). Note that the betas are high, implying high sensitivity to market movements.  The CAGR (Compound Annual Growth Rate) shows substantial growth over the periods, but the MDD (Maximum Drawdown) highlights periods of significant risk.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 10.0% | 55.6% | -19.0% | 0.1 | 67.7 |
| 2016-2018  | 38.0% | 58.6% | 20.0% | -0.1 | 95.1 |
| 2017-2019  | 49.0% | 58.6% | 19.0% | 0.3 | 110.4 |
| 2018-2020  | 51.0% | 58.6% | 25.0% | 0.2 | 144.7 |
| 2019-2021  | 105.0% | 60.7% | 50.0% | 0.3 | 240.3 |
| 2020-2022  | 100.0% | 65.0% | 94.0% | 0.3 | 322.6 |
| 2021-2023  | 138.0% | 65.0% | 122.0% | 0.3 | 519.2 |
| 2022-2024  | 156.0% | 72.1% | 139.0% | 0.3 | 692.0 |
| 2023-2025  | 119.0% | 76.9% | 106.0% | 0.2 | 647.4 |


**2. Recent Price Movement:**

* **Closing Price:** $720.91
* **5-Day Moving Average:** $732.56
* **20-Day Moving Average:** $803.37
* **60-Day Moving Average:** $829.06

The price is below all three moving averages, indicating a possible bearish trend.  The recent price change of -$4.35 from the previous close suggests a recent drop.

**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.4292 (Medium Risk)
* **RSI:** 28.05 (Oversold territory, suggesting potential for a price bounce)
* **PPO:** -1.30 (Negative, confirming bearish momentum)
* **20-Day Relative Divergence Change:** -2.2% (Short-term downward trend)
* **Expected Return (Long-term):** 80.0% (This represents an expected outperformance relative to the S&P 500 over a long-term investment horizon of 2 years or more.)  The large price drop (-$4.35) suggests a potential market event may have impacted this.  However, given the RSI being in oversold territory, a price bounce could be imminent.

**4. Recent Earnings Analysis:**

The earnings data shows some volatility.  There's a significant drop in EPS in the periods of 2023-11-02 and 2024-10-30 (-$0.06).  Overall, the revenue shows steady growth, while EPS is more variable.  Further analysis is needed to fully understand the reasons behind this variability.

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-10-30 | 1.08 | $11.44B       |
| 2024-08-08 | 3.29 | $11.30B       |
| 2024-04-30 | 2.49 | $8.77B        |
| 2023-11-02 | -0.06 | $9.50B        |
| 2024-10-30 | -0.06 | $9.50B        | *(Duplicate Entry)*


**5. Financial Information:**

Revenue shows consistent growth, although there is a slight decrease in Q1 2024. Profit margins remain high and stable across the quarters. Equity shows some growth with a dip in Q2 2024. ROE (Return on Equity) is highly variable, needing further investigation into the underlying drivers.  The high profit margins suggest strong operational efficiency.


| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|---------------|
| 2024-12-31 | $13.53B     | 82.24%        |
| 2024-09-30 | $11.44B     | 81.02%        |
| 2024-06-30 | $11.30B     | 80.80%        |
| 2024-03-31 | $8.77B      | 80.91%        |
| 2023-12-31 | $9.35B      | 80.88%        |

| Quarter     | Equity      | ROE           |
|-------------|-------------|---------------|
| 2024-12-31 | $14.19B     | 31.07%        |
| 2024-09-30 | $14.24B     | 6.81%         |
| 2024-06-30 | $13.56B     | 21.88%        |
| 2024-03-31 | $12.81B     | 17.51%        |
| 2023-12-31 | $10.77B     | 20.33%        |


**6. Overall Analysis:**

LLY has demonstrated strong historical outperformance compared to the S&P 500.  However, recent price action suggests a possible bearish trend, supported by technical indicators (RSI, PPO).  While the long-term outlook remains positive (indicated by the high expected return), the recent earnings volatility and the significant price drop requires further investigation to understand the underlying factors and assess the potential risks.  A deeper dive into the reasons behind the EPS fluctuations and the variability in ROE is crucial before making any investment decisions.  The current market position suggests caution, and a wait-and-see approach while monitoring further developments might be prudent.  However, the oversold RSI could indicate a short-term bounce.
